Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIDENT-3: Repotrectinib vs Crizotinib in ROS1-positive NSCLC
2023-505604-32-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Repotrectinib arm with Crizotinib arm (2 arms). Primary endpoint: Progression-free survival (PFS) per BICR according to RECIST v1.1. Planned start Jan 2024; status: authorised.
02
Drugs
repotrectinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-505604-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505604-32-00.